Literature DB >> 34218271

FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.

Dan-Yun Ruan1,2, Ting Li1, Ying-Nan Wang1,3, Qi Meng1, Yang Li2, Kai Yu1, Min Wang1, Jin-Fei Lin1, Li-Zhi Luo1, De-Shen Wang1, Jun-Zhong Lin4, Long Bai1, Ze-Xian Liu1, Qi Zhao1, Xiang-Yuan Wu2, Huai-Qiang Ju5,6, Rui-Hua Xu7,8.   

Abstract

Fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m6A) demethylase, participates in tumor progression and metastasis in many malignancies, but its role in colorectal cancer (CRC) is still unclear. Here, we found that FTO protein levels, but not RNA levels, were downregulated in CRC tissues. Reduced FTO protein expression was correlated with a high recurrence rate and poor prognosis in resectable CRC patients. Moreover, we demonstrated that hypoxia restrained FTO protein expression, mainly due to an increase in ubiquitin-mediated protein degradation. The serine/threonine kinase receptor associated protein (STRAP) might served as the E3 ligase and K216 was the major ubiquitination site responsible for hypoxia-induced FTO degradation. FTO inhibited CRC metastasis both in vitro and in vivo. Mechanistically, FTO exerted a tumor suppressive role by inhibiting metastasis-associated protein 1 (MTA1) expression in an m6A-dependent manner. Methylated MTA1 transcripts were recognized by an m6A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), which then stabilized its mRNA. Together, our findings highlight the critical role of FTO in CRC metastasis and reveal a novel epigenetic mechanism by which the hypoxic tumor microenvironment promotes CRC metastasis.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34218271      PMCID: PMC8376648          DOI: 10.1038/s41388-021-01916-0

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  FTO-Dependent N 6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.

Authors:  Hao Huang; Yinu Wang; Manoj Kandpal; Guangyuan Zhao; Horacio Cardenas; Yanrong Ji; Anusha Chaparala; Edward J Tanner; Jianjun Chen; Ramana V Davuluri; Daniela Matei
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

Review 2.  The tumor microenvironment.

Authors:  Cynthia E Weber; Paul C Kuo
Journal:  Surg Oncol       Date:  2011-10-01       Impact factor: 3.279

3.  Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Authors:  Rui-Hua Xu; Kei Muro; Satoshi Morita; Satoru Iwasa; Sae Won Han; Wei Wang; Masahito Kotaka; Masato Nakamura; Joong Bae Ahn; Yan-Hong Deng; Takeshi Kato; Sang-Hee Cho; Yi Ba; Hiroshi Matsuoka; Keun-Wook Lee; Tao Zhang; Yasuhide Yamada; Junichi Sakamoto; Young Suk Park; Tae Won Kim
Journal:  Lancet Oncol       Date:  2018-03-16       Impact factor: 41.316

Review 4.  The AlkB Family of Fe(II)/α-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond.

Authors:  Bogdan I Fedeles; Vipender Singh; James C Delaney; Deyu Li; John M Essigmann
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

Review 5.  MTA1--a stress response protein: a master regulator of gene expression and cancer cell behavior.

Authors:  Rui-An Wang
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 6.  RNA N6-methyladenosine modification in cancers: current status and perspectives.

Authors:  Xiaolan Deng; Rui Su; Hengyou Weng; Huilin Huang; Zejuan Li; Jianjun Chen
Journal:  Cell Res       Date:  2018-04-23       Impact factor: 25.617

7.  RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.

Authors:  Yi Niu; Ziyou Lin; Arabella Wan; Honglei Chen; Heng Liang; Lei Sun; Yuan Wang; Xi Li; Xiao-Feng Xiong; Bo Wei; Xiaobin Wu; Guohui Wan
Journal:  Mol Cancer       Date:  2019-03-28       Impact factor: 27.401

Review 8.  Functions of N6-methyladenosine and its role in cancer.

Authors:  Liuer He; Huiyu Li; Anqi Wu; Yulong Peng; Guang Shu; Gang Yin
Journal:  Mol Cancer       Date:  2019-12-04       Impact factor: 27.401

9.  Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.

Authors:  Huilin Huang; Hengyou Weng; Wenju Sun; Xi Qin; Hailing Shi; Huizhe Wu; Boxuan Simen Zhao; Ana Mesquita; Chang Liu; Celvie L Yuan; Yueh-Chiang Hu; Stefan Hüttelmaier; Jennifer R Skibbe; Rui Su; Xiaolan Deng; Lei Dong; Miao Sun; Chenying Li; Sigrid Nachtergaele; Yungui Wang; Chao Hu; Kyle Ferchen; Kenneth D Greis; Xi Jiang; Minjie Wei; Lianghu Qu; Jun-Lin Guan; Chuan He; Jianhua Yang; Jianjun Chen
Journal:  Nat Cell Biol       Date:  2018-02-23       Impact factor: 28.824

View more
  16 in total

Review 1.  Crosstalk between m6A regulators and mRNA during cancer progression.

Authors:  Xiaodong Niu; Yuan Yang; Yanming Ren; Shengtao Zhou; Qing Mao; Yuan Wang
Journal:  Oncogene       Date:  2022-08-25       Impact factor: 8.756

2.  [m7G-lncRNAs are potential biomarkers for prognosis and tumor microenvironment in patients with colon cancer].

Authors:  S Chen; R Dong; Y Li; H Wu; M Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 3.  The Functional Roles and Regulation of Circular RNAs during Cellular Stresses.

Authors:  Yueh-Chun Lee; Wei-Yu Wang; Hui-Hsuan Lin; Yi-Ren Huang; Ya-Chi Lin; Kuei-Yang Hsiao
Journal:  Noncoding RNA       Date:  2022-05-27

Review 4.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 5.  N6-methyladenosine RNA modification and its interaction with regulatory non-coding RNAs in colorectal cancer.

Authors:  Yiling Ge; Tong Liu; Chuntao Wang; Yanqiu Zhang; Siyi Xu; Yiyi Ren; Yanlu Feng; Lihong Yin; Yuepu Pu; Geyu Liang
Journal:  RNA Biol       Date:  2021-10-21       Impact factor: 4.766

6.  FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.

Authors:  Jiapeng Huang; Wei Sun; Zhihong Wang; Chengzhou Lv; Ting Zhang; Dalin Zhang; Wenwu Dong; Liang Shao; Liang He; Xiaoyu Ji; Ping Zhang; Hao Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-28

7.  Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis.

Authors:  Qiaoling Xiao; Li Lei; Jun Ren; Meixi Peng; Yipei Jing; Xueke Jiang; Junpeng Huang; Yonghong Tao; Can Lin; Jing Yang; Minghui Sun; Lisha Tang; Xingyu Wei; Zailin Yang; Ling Zhang
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

8.  m6A methyltransferase KIAA1429 acts as an oncogenic factor in colorectal cancer by regulating SIRT1 in an m6A-dependent manner.

Authors:  Yuan Zhou; Zhengda Pei; Aizezi Maimaiti; Linyi Zheng; Zhongcheng Zhu; Mengxiang Tian; Zhongyi Zhou; Fengbo Tan; Qian Pei; Yuqiang Li; Wenxue Liu
Journal:  Cell Death Discov       Date:  2022-02-25

9.  Downregulation of m6 A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness.

Authors:  Catarina Guimarães-Teixeira; João Lobo; Vera Miranda-Gonçalves; Daniela Barros-Silva; Cláudia Martins-Lima; Sara Monteiro-Reis; José Pedro Sequeira; Isa Carneiro; Margareta P Correia; Rui Henrique; Carmen Jerónimo
Journal:  Mol Oncol       Date:  2022-03-24       Impact factor: 7.449

Review 10.  The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.

Authors:  Huan Tong; He Wei; Alhaji Osman Smith; Juan Huang
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.